Dasatinib & Quercetin as a Senolytic Therapy - Quick Reference Sheet
evipedia.aidev
← Back

Dasatinib & Quercetin as a Senolytic Therapy

Created on 08/10/2026 – Quick Reference based on Evidence Review created using AI4L / Grok 4 – Audit

Dasatinib plus quercetin is an experimental intermittent therapy pairing a leukemia drug with a plant flavonoid to clear aging cells. Short courses can lower aging-cell markers in tissue under medical supervision; functional and longevity benefits remain unproven. Risks follow the cancer drug—blood counts, fluid retention, bleeding, and drug interactions. Use remains off-label and clinician-supervised—not a settled rejuvenation regimen. (Full Review)

Protocol

Dose
D 100 mg + Q 1,000–1,250 mg
Once daily on 3 consecutive dosing days; quercetin often split
Schedule
Intermittent pulses
Single 3-day pulse or weekly ×3 weeks; clinic variants every 1–3 months
Supervision
Clinician-prescribed only
Off-label use; morning with food; grapefruit products excluded on dosing days
Time to effect
Tissue markers
~11 days
After a single 3-day pulse
Function
Weeks
When functional changes reported in pilots
Clinical outcomes
Multi-month horizon
Durable longevity benefit unproven in healthy adults

Benefits

Contraindications
  • Pregnancy and breastfeeding
  • Active uncontrolled infection
  • Significant cytopenias
  • Recent major surgery or non-healing wounds
  • Known dasatinib hypersensitivity
  • Severe hepatic impairment without specialist oversight
  • Children/adolescents (except oncology indications)
    •
Key Interactions
  • Strong CYP3A4 inhibitors (ketoconazole, itraconazole, voriconazole, ritonavir, cobicistat, clarithromycin, grapefruit juice)
  • Strong CYP3A4 inducers (rifampin, carbamazepine, phenytoin, St. John’s wort)
  • Antacids and acid-reducing agents (separate antacids ≥2 hours; review PPIs/H2 blockers)
  • Anticoagulants and antiplatelets (warfarin, DOACs, clopidogrel, aspirin at antiplatelet doses)
  • QT-prolonging drugs (certain antiarrhythmics, antipsychotics, macrolides)
  • Other CYP3A4/P-gp substrate drugs
  • Supplements with additive bleeding or CYP effects (high-dose fish oil, ginkgo, high-dose vitamin E, curcumin in some contexts)
  • Other senolytics or cytotoxic agents (fisetin megadoses, navitoclax, chemotherapy)
    •

Risk & Side Effects

  • High: Dasatinib-class adverse effects at oncology doses and schedules
    •
  • Medium: Gastrointestinal symptoms, headache, fatigue, rash, and respiratory complaints on intermittent D+Q; drug–drug interaction risk via CYP3A4 and QT/bleeding pathways
    •
  • Low: Transient effects on blood counts and inflammatory markers after a dosing pulse; off-target effects on non-senescent cells
    •
  • Speculative: Long-term cumulative harm from repeated dasatinib pulses in non-cancer populations; harm from unregulated or self-directed sourcing of dasatinib
    •

Monitoring

Marker Target Why
CBC with differential (WBC, ANC, hemoglobin, platelets) Within age-appropriate lab reference; investigate any grade ≥2 cytopenia Detect dasatinib-related marrow suppression
Comprehensive metabolic panel (ALT/AST, bilirubin, creatinine/eGFR) Liver enzymes near mid-normal; eGFR stable for the individual Hepatic metabolism and renal comorbidity safety
ECG (QTc) QTc within normal limits for sex; no new ischemic changes Arrhythmia/ischemia risk screen
hs-CRP or selected inflammatory markers Lower is generally better for residual risk context Indirect inflammation context
Research senescence markers (T-cell p16, SASP panel) when available Lab-specific; higher burden may predict response Stratify biological senescence load

Cadence: Baseline CBC, CMP, and ECG when indicated; labs before and shortly after first pulses, then around each course or every 3–6 months if repeating

Qualitative Assessment

  • Energy and exercise tolerance over weeks after a pulse
  • Dyspnea, cough, peripheral edema, or rapid weight gain
  • Bruising, bleeding gums, petechiae
  • Sleep quality and mood around dosing days
  • Subjective recovery after illness or training load
Not medical advice. Educational distillation of a single evidence review. Confirm any decision with a qualified clinician, especially in the presence of prescription drugs or chronic conditions.